Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2107MR)

This product GTTS-WQ2107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2107MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10307MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ9619MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ11095MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ11729MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ13084MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8556MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ3548MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ4395MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW